Porter Alliance for Innovative Medicines will be equipped with $130m to advance research from Stanford’s Innovative Medicines Accelerator.

Stanford University and investment firm Deerfield Management entered into a collaboration agreement yesterday and launched Porter Alliance for Innovative Medicines with up to $130m in capital. Porter Alliance will look to accelerate translational research, particularly from Stanford’s Innovative Medicines Accelerator, into clinical therapeutics. It is the latest such collaboration that Deerfield has inked over the past several years. James Flynn, managing partner at Deerfield, previously spoke to Global University Venturing about the firm’s ambitions surrounding these initiatives. In a prepared statement, Flynn said about the latest collaboration: “We are proud to collaborate with Stanford University to help build the bridge that connects basic research to patient cures. “It requires tremendous infrastructure and support to change the probability of success and speed to market for discovery. Through Porter Alliance, Stanford investigators will receive the necessary resources, expertise and management to advance their outstanding science.” Lloyd Minor, dean of Stanford University’s School of Medicine, added: “The Porter Alliance for Innovative Medicines aims to close a historic gap between scientific research and clinical care. “This collaboration with Deerfield Management will ensure that Stanford’s breakthroughs in biomedical research translate rapidly to treatments and cures for patients.” Chaitan Khosla, director of the Innovative Medicines Accelerator and professor of chemistry and of chemical engineering at Stanford University, commented: “The Innovative Medicines Accelerator is helping Stanford faculty transform their discoveries into prototype medicines, and we must do whatever we can to ensure those medicines get to the patients who need them. “I am excited and grateful that the Porter Alliance for Innovative Medicines will serve as a bridge between our promising prototypes and approved therapeutics.” – Image of Stanford Medical School courtesy of Ian Mackey

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).